Amri

Cequent Pharmaceuticals, a privately held biopharmaceutical company based in Cambridge, Massachusetts, is at the forefront of developing novel therapeutics aimed at preventing and treating a variety of human diseases, including inflammatory diseases and cancer. Established in 2006, the company leverages its proprietary TransKingdom RNA interference (tkRNAi) technology to target specific disease-causing genes safely and effectively using non-pathogenic bacteria as delivery vehicles. The tkRNAi platform enables the development of drug candidates that can silence one or more cellular genes simultaneously, offering a powerful alternative to traditional small molecules and monoclonal antibodies. With its foundation rooted in groundbreaking scientific research from the Institut Pasteur in Paris and Beth Israel Deaconess Medical Center at Harvard Medical School, Cequent is poised to make significant advancements in the biopharmaceutical landscape. Generated from the website

AVEO Pharmaceuticals Inc. is an oncology-focused biopharmaceutical company based in Cambridge, MA, dedicated to developing innovative medicines aimed at improving the lives of cancer patients. The company is committed to pursuing advanced solutions in cancer treatment through its research and development efforts. As part of its mission, AVEO emphasizes a culture of collaboration and innovation, working closely with partners and scientific advisors to enhance its therapeutic offerings. The company is driven by a passion for delivering better outcomes for patients facing the challenges of cancer. Generated from the website

Formerly known as Millennium Pharmaceuticals